Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.
Related Articles
Treatment Sequencing Strategies in R/R Multiple Myeloma
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer
Oncogene – A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer
Top AML highlights from ASH 2024: menin inhibitors & gilteritinib versus midostaurin in induction
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on the recent developments in the treatment of acute myeloid leukemia (AML), sharing…
Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRD
With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates…
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review
Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to…
Donate to Moffitt Cancer Center
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many…
Thousands of women with breast cancer may not need ANY treatment
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.